[{"from": "human", "value": "Provide a description of this molecule. [C][C][=C][C][=Branch2][Ring1][=Branch1][=C][Branch1][=N][C][=C][Ring1][=Branch1][C][C][C][N][C][C][Ring1][=Branch1][O][C][Branch1][C][C][C][N][C][=N][C][=C][Branch2][Ring1][N][C][=Branch1][Ring2][=N][Ring1][=Branch1][N][C][=C][C][=C][C][=C][Ring1][=Branch1][S][=Branch1][C][=O][=Branch1][C][=O][C][Branch1][C][C][C][Cl]"}, {"from": "gpt", "value": "The molecule is an orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ceritinib binds to and inhibits wild-type ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to both the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types."}]